Wednesday, September 2, 2009

Mkt and Stem Cells Down Again Wednesday 9.2

Wednesday 9.2.09:
DOW -30(.3%) @9,281..NAS -1.8(.09%) @1,967..SP500 -3.3(.33%) @994.75

BIO-Stem Index: -2.47(-1.8%) @137.18 (+37.18% ytd)
BIO-ETF Index: -.22(-.2%) @110.63 (+10.64% ytd
[Stem cell index beating biotech by 24%]

The market was flat most of the day Wednesday, then fell .3% at the close. Stem cells fell 1.8% however (our index), while the biotech ETFs only fell .2%. Stem cell stocks overall: only 14 up, 15 down, 2 unchanged. MEDX is now gone, acquired by Bristol-Myers Squibb. SVA gave back 18.5% today, after doubling in a week.

Stem Cell Stocks (14 up, 15 down, 2 n.c.)
Big Winners: ATHX +2.1%, CUR +2.8%, GERN +2.2%, LMNX +2%
Losers: ARIA -3.4%, AVII -14.4%, OSIR -2.8%, SQNM -2.7%

Swine Flu Stocks
AVII -14.4%, BCRX -4.5%, DVAX +2.4%, GILD +.4%, INHX -8.3, INO -1.4%, NVAX -10.7%, SIGA +5%, SVA -18.5%
Other Flu: APT -6.9%, HEB -5.2%, VICL -7.7%

Other Biotech
Big Winners: ACAD +7.5%, CRXL +2.4%, DSCO +2.1%, ENZN +2.1%, EXEL +2.5%, IMMU +2.9%, KVA +31.5%, LMNX +2%, NBIX +9.4%, NEOG +7.95%, ONCY +2.3%, PGNX +2.1%, PLX +3.4%, SGMO +4.6%, SIGA +5%
Losers: ANDS -10.2%, ARIA -3.4%, CPRX -13.1%, HGSI -5.9%, JAV -5.4%, JAZZ -4.3%, TRBN -9.7%, XOMA -4.8%

Big Volume: AFFX, AVII, OSIR, BCRX, NVAX, SIGA, SVA, APT, CRXL, PURE, ACAD, ALKS, ENZN, EXEL, IMMU, MED, NBIX, NEOG, PLX, SGEN, SIGA

New Intraday Highs: NEOG (that's all..)

Disclosure: Long SPPI (drug decision due soon, another in Oct)

0 comments:

Disclaimer

This is not a solicitation or recommendation to buy or sell any stock. We are not registered investment advisors, and the site does not receive any compensation for any posts, endorsements, or listings. All investments carry risk, and your own individual situation should determine your strategy. Only invest funds you can afford to lose.

The Author at EZines

STEM CELLS EXPRESS

Visitor Map

Related Sites

World Markets Summary

Why We Invest

A company issuing stock gets it's money when the stock goes public, called IPO for Initial Public Offering. However, if the stock takes off due to future expectations, the company can capitalize by issuing more stock and raising money near the current price, so investing in these small biotech companies increases their chances of succeeding by raising enough additonal capital that they don't need to take on debt.

Then when promising drugs are approved and released, the subsequent income produced drives the stock price higher, and all investors and employees benefit and can either invest more in the industry or perhaps realize a goal in life.

1000 DVDs to See

About Me

My Photo
Artist, photographer, composer, author, blogger, metaphysician
©2009, William L. Sinclair, All Rights Reserved

  © Blogger template 'Froggy' by Ourblogtemplates.com 2008

Back to TOP